Antitumor effect of transcatheter arterial embolization in combination with sorafenib in a rabbit VX2 liver tumor model
Project/Area Number |
25861084
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Radiation science
|
Research Institution | Shiga University of Medical Science |
Principal Investigator |
TOMOZAWA Yuki 滋賀医科大学, 医学部, 助教 (90585689)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | ソラフェニブ / 肝動脈塞栓 / 肝動脈塞栓術 |
Outline of Final Research Achievements |
Using a VX2 liver tumor model, we investigated antitumor effect of the combination of TACE with sorafenib and suitable timing parameters when using sorafenib to enhance the anti-tumor effects of TAE. In conclusion, we suggest that a combination of sorafenib with TAE is a more effective treatment than sorafenib or TACE alone and the ideal time of TAE is prior to or early after commencement of administration Sorafenib.
|
Report
(3 results)
Research Products
(2 results)